Director at Solid Biosciences (NASDAQ: SLDB) granted 77,500 options

Rhea-AI Filing Summary

Solid Biosciences director Ian F. Smith received a grant of stock options covering 77,500 shares of common stock. The Director Stock Option has an exercise price of $6.61 per share and, after this grant, Smith holds options on 77,500 shares directly.

The option was granted on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders after the grant date. Any remaining unvested portion will also vest automatically upon specified change in control events. The option expires on June 10, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SMITH IAN F

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	77,500	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 77,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 77,500 shares Exercise price: $6.61 per share Expiration date: June 10, 2036 +3 more

6 metrics

Options granted 77,500 shares Director Stock Option grant on June 10, 2026

Exercise price $6.61 per share Director Stock Option strike price

Expiration date June 10, 2036 Option term end date

Total options after grant 77,500 shares Total shares underlying this option following transaction

Vesting trigger Earlier of 1 year or next annual meeting Full vesting schedule from grant date June 10, 2026

Change in control vesting 100% of unvested portion Automatic vesting upon specified change in control events

Key Terms

Director Stock Option, exercise price, change in control events, annual meeting of stockholders

4 terms

Director Stock Option financial

"security_title: "Director Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "6.6100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control events financial

"will vest automatically as to 100% of the unvested portion of such option upon specified change in control events"

annual meeting of stockholders financial

"immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH IAN F

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$6.61	06/10/2026		A		77,500		(1)	06/10/2036	Common Stock	77,500	$0.00	77,500	D

Explanation of Responses:

1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

	/s/ by Kimberly Cornwell as attorney-in-fact for Ian F. Smith	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Ian F. Smith report in this Solid Biosciences (SLDB) Form 4?

Ian F. Smith reported receiving a grant of stock options for 77,500 shares of Solid Biosciences common stock. These director options are a form of equity compensation and give him the right to buy shares at a fixed exercise price in the future.

How many Solid Biosciences (SLDB) shares are covered by the new options?

The new option grant covers 77,500 shares of common stock. After this grant, Smith’s reported holdings in this option total 77,500 shares, reflecting his entire position in this specific award following the transaction.

What is the exercise price of Ian F. Smith’s new Solid Biosciences options?

The Director Stock Option has an exercise price of $6.61 per share. This means Smith can purchase Solid Biosciences common stock at $6.61 for each share covered by the option, subject to vesting and before the option’s expiration date.

When do the new Solid Biosciences (SLDB) director options vest?

The options vest in full on the earlier of one year after June 10, 2026, or immediately before the next annual stockholders’ meeting. Any remaining unvested portion also vests automatically upon specified change in control events affecting the company.

When do Ian F. Smith’s newly granted Solid Biosciences options expire?

The granted Director Stock Option expires on June 10, 2036. Smith may exercise the vested portion any time before that expiration date, subject to the option’s terms and applicable company or regulatory requirements governing such exercises.

Is this Solid Biosciences (SLDB) Form 4 an open-market stock purchase or sale?

No, this Form 4 reflects a grant of stock options as compensation, coded as a grant, award, or other acquisition. It is not an open-market purchase or sale of existing shares, but the creation of a right to buy shares in the future.